
News|Articles|November 15, 2012
Sanofi lowers price of Zaltrap after Sloan-Kettering refusal to use it
Sanofi is lowering the price of ziv-aflibercept (Zaltrap) for previously treated colorectal cancer by half after physicians at Memorial Sloan Kettering Cancer Center (MSKCC) said that they would not use the drug, according to The New York Times.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicare’s first-year payments for social needs showed high use by primary care but many claims were denied
2
See which Minnesota healthcare CEOs signed letter calling for 'immediate deescalation of tensions' following shooting of Alex Pretti
3
House passes funding bill that includes PBM reform
4
Do you know what’s in your contracts?
5




























